Landsteiner Genmed Obtains 2,055M € of Non-Dilutive Funding from Next Generation EU Funds to Develop New Anticancer Immunomodulatory Agents

Seville, Spain, January 27, 2023 – The biopharmaceutical company Landsteiner Genmed (LGM) has announced that it has obtained 2,055M € of non-dilutive funding from Next Generation EU Funds managed by the Ministry of Science and Innovation of the Government of Spain (Proyectos de colaboración público-privada, 2022) to study the anticancer effects of new molecules with immunomodulatory properties.

This project aims to further investigate LGC-2091 as a novel anticancer immunotherapeutic and identify new anticancer immunotherapeutic candidates based on selective inhibition of cysteine proteases.

LGM, owner of LGC-2091, has created a consortium integrated by Prof Dr Santos Mañes’s Lab from the National Centre of Biotechnology (CNB), Prof Eddy Sotelo’s lab from Center for Research in Biological Chemistry and Molecular Materials (CiQUS), and Prof Luis Paz-Ares from the Research Institute Hospital 12 de Octubre (i+12) to develop this project. LGM will be the coordinator of the project.

Grant CPP2021-009090 funded by MCIN/AEI (10.13039/501100011033) and European Union NextGenerationEU/PRTR.

If you would like more information about our studies

Ask us